Deutsche Bank Ag\ Ardelyx, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Ardelyx, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 261,647 shares of ARDX stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

261,647

Previous 1,451,614 81.98%

Holding current value

$1.29 Million

Previous $10.8 Million 83.25%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$5.28 - $7.57 $6.28 Million - $9.01 Million	-1,189,967 Reduced 81.98%	261,647 $1.8 Million
Q2 2024 Aug 14, 2024	BUY	$5.89 - $9.31 $687,386 - $1.09 Million	116,704 Added 8.74%	1,451,614 $10.8 Million
Q1 2024 May 15, 2024	BUY	$6.05 - $9.74 $1.22 Million - $1.97 Million	201,763 Added 17.81%	1,334,910 $9.74 Million
Q4 2023 Feb 14, 2024	SELL	$3.29 - $6.64 $57,890 - $116,837	-17,596 Reduced 1.53%	1,133,147 $7.03 Million
Q3 2023 Nov 09, 2023	BUY	$3.3 - $4.83 $67,452 - $98,725	20,440 Added 1.81%	1,150,743 $4.7 Million
Q2 2023 Aug 14, 2023	BUY	$3.23 - $4.95 $740,958 - $1.14 Million	229,399 Added 25.46%	1,130,303 $3.83 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $243,344 - $434,932	90,800 Added 11.21%	900,904 $4.32 Million
Q2 2022 Aug 11, 2022	SELL	$0.51 - $1.17 $25,891 - $59,397	-50,767 Reduced 5.9%	810,104 $478,000
Q1 2022 May 13, 2022	SELL	$0.65 - $1.18 $69,280 - $125,771	-106,586 Reduced 11.02%	860,871 $922,000
Q4 2021 Feb 11, 2022	BUY	$0.86 - $1.7 $86,249 - $170,493	100,290 Added 11.57%	967,457 $1.06 Million
Q3 2021 Nov 04, 2021	SELL	$1.27 - $8.17 $5,571 - $35,841	-4,387 Reduced 0.5%	867,167 $1.15 Million
Q2 2021 Aug 11, 2021	BUY	$6.55 - $8.98 $2.05 Million - $2.81 Million	312,661 Added 55.94%	871,554 $6.61 Million
Q1 2021 May 13, 2021	SELL	$6.1 - $7.69 $94,080 - $118,602	-15,423 Reduced 2.69%	558,893 $3.7 Million
Q4 2020 Feb 16, 2021	BUY	$5.05 - $7.1 $625,583 - $879,533	123,878 Added 27.5%	574,316 $3.72 Million
Q3 2020 Nov 12, 2020	BUY	$5.25 - $7.08 $185,146 - $249,683	35,266 Added 8.49%	450,438 $2.37 Million
Q2 2020 Aug 13, 2020	BUY	$5.37 - $8.11 $1.53 Million - $2.3 Million	284,171 Added 216.92%	415,172 $2.87 Million
Q1 2020 May 14, 2020	BUY	$4.35 - $8.79 $444,187 - $897,564	102,112 Added 353.46%	131,001 $744,000
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $69,710 - $136,619	16,480 Added 132.81%	28,889 $215,000
Q3 2019 Nov 14, 2019	SELL	$2.15 - $6.28 $63,035 - $184,123	-29,319 Reduced 70.26%	12,409 $57,000
Q2 2019 Aug 14, 2019	SELL	$2.49 - $3.73 $183,931 - $275,527	-73,868 Reduced 63.9%	41,728 $111,000
Q1 2019 May 15, 2019	SELL	$1.88 - $3.35 $951,812 - $1.7 Million	-506,283 Reduced 81.41%	115,596 $323,000
Q4 2018 Feb 14, 2019	BUY	$1.66 - $4.16 $846,077 - $2.12 Million	509,685 Added 454.29%	621,879 $1.11 Million
Q3 2018 Dec 21, 2021	BUY	$3.75 - $4.65 $76,953 - $95,422	20,521 Added 22.38%	112,194 $487,000
Q3 2018 Nov 14, 2018	BUY	$3.75 - $4.65 $31,740 - $39,357	8,464 Added 10.17%	91,673 $398,000
Q2 2018 Apr 21, 2020	BUY	$3.7 - $5.8 $66,204 - $103,779	17,893 Added 27.39%	83,209 $308,000
Q2 2018 Aug 14, 2018	SELL	$3.7 - $5.8 $482,831 - $756,871	-130,495 Reduced 66.64%	65,316 $241,000
Q1 2018 Oct 18, 2019	BUY	$5.05 - $7.9 $64,453 - $100,827	12,763 Added 6.97%	195,811 $987,000
Q1 2018 May 15, 2018	BUY	$5.05 - $7.9 $52,681 - $82,412	10,432 Added 6.04%	183,048 $923,000
Q4 2017 Feb 14, 2018	BUY	$4.85 - $7.8 $438,590 - $705,361	90,431 Added 110.03%	172,616 $1.14 Million
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $357,504 - $468,454	82,185	82,185 $459,000

Others Institutions Holding ARDX

# of Institutions

219

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $761M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account